C3L-02348
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 58.32169747
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.340
- PROTEIN_SECRETION+0.300
- FATTY_ACID_METABOLISM+0.280
- INTERFERON_ALPHA_RESPONSE+0.270
- ALLOGRAFT_REJECTION+0.260
- BILE_ACID_METABOLISM+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
- INTERFERON_GAMMA_RESPONSE+0.170
- ANDROGEN_RESPONSE+0.150
- HEME_METABOLISM+0.140
Top 10 suppressed
- MYC_TARGETS_V2-0.630
- E2F_TARGETS-0.570
- G2M_CHECKPOINT-0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- MYC_TARGETS_V1-0.440
- ANGIOGENESIS-0.420
- MTORC1_SIGNALING-0.390
- HYPOXIA-0.330
- GLYCOLYSIS-0.320
- APICAL_SURFACE-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | dcabd821.c5d5.4a97.b657.0612d6a4439d | — | cohortA1 | 0.833 |
| 2 | TCGA-67-6217-01A-11R-1755-07 | — | cohortA1 | 0.815 |
| 3 | 7c025d06-2593-493c-b4a5-9f976149b0e2 | — | — | 0.810 |
| 4 | C3L-02350 | — | cohortA1 | 0.806 |
| 5 | SRR12475115 | — | — | 0.802 |
| 6 | SRR12475148 | — | — | 0.797 |
| 7 | TCGA-78-7539-01A-11R-2066-07 | — | cohortA1 | 0.794 |
| 8 | TCGA-55-7573-01A-11R-2039-07 | — | cohortA1 | 0.792 |
| 9 | SRR12475121 | — | — | 0.790 |
| 10 | TCGA-44-5645-01A-01R-1628-07 | — | cohortA1 | 0.789 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.260 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.170 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| COMPLEMENT | 0.070 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.070 | Inavolisib | — uncovered |
| COAGULATION | 0.060 | Binimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.030 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.030 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |